EGFR Targeting of Liposomal Doxorubicin Improves Recognition and Suppression of Non-Small Cell Lung Cancer.
Ernest MolesDavid W ChangFriederike M MansfeldAlastair DulyKathleen KimptonAmy LoganChristopher B HowardKristofer J ThurechtMaria KavallarisPublished in: International journal of nanomedicine (2024)
EGFR targeting represents a successful approach to enhance the selectivity and therapeutic potency of liposomal chemotherapy toward NSCLC.